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Abstract (199) 
 
Purpose:The identification of BRCA1, BRCA2 or mismatch repair (MMR)  
pathogenic gene variants in familial breast/ovarian/colorectal cancer families 
facilitates predictive genetic testing of at risk relatives. However, controversy still 
exists regarding overall lifetime risks of cancer in individuals testing positive.  
Methods:We assessed the penetrance of BRCA1, BRCA2, MLH1 and MSH2 mutations 
in men and women using Bayesian calculations based on ratios of positive to negative 
pre-symptomatic testing by 10-year age cohorts. Mutation position was also assessed 
for BRCA1/BRCA2. 
Results:Using results from 2264 pre-symptomatic tests in First Degree Relatives 
(FDRs) of mutation carriers in  BRCA1 and BRCA2 and 646 FDRs of patients with 
MMR mutations, we assessed overall associated cancer  penetrance to age of 68 years 
as 73% (95% CI:61-82%) for BRCA1, 60% (95%CI:49-71%) for BRCA2, 95% (95% 
CI:76-99%) for MLH1 and 61% (95% CI:49-76%) for MSH2. There was no evidence 
for significant penetrance for males in BRCA1 or BRCA2 families and males had 
equivalent penetrance to Lynch syndrome females. Mutation position and degree of 
family history influenced penetrance in BRCA2 but not BRCA1. 
Conclusion:We describe a new method for assessing penetrance in cancer prone 
syndromes. Results are in keeping with published prospective series and present 
modern day estimates for overall disease penetrance that bypasses retrospective series 
biases. 
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Introduction 
 
Since the original identification of the BRCA1, BRCA2, MSH2 and MLH1 genes [1-4] 
between 1993-1995, much research, particularly in BRCA1/2,  has focussed on 
estimations of overall lifetime cancer risk associated with mutations in these genes [5-
10]. Clearly, calculated cancer risks are dependent on the method of ascertainment of 
the families studied. Therefore, breast/ovarian cancer risks in large familial 
breast/ovarian cancer kindreds with BRCA1/BRCA2 mutations [5,9,10], were 
substantially greater than risks calculated from population based studies [6,7,8]. In the 
high-risk families that recruited to the Breast Cancer Linkage Consortium (BCLC) 
cohort, BRCA1 and BRCA2 mutations were estimated to cause a cumulative lifetime 
risk of breast cancer by age 70 years of 85–87% and 77–84% respectively [5,9,10]. 
However, estimates of breast cancer risks by age 70 years derived from previous 
population based studies, are much lower at 28-60% [6-8] for BRCA1, and 25-60% for 
BRCA2. It has been suggested that even these studies may overestimate the effect of the 
BRCA1/2 mutation alone [11]. A meta-analysis of population based studies provided 
risks to 70 years of 57% (95% CI, 47% to 66%) for BRCA1 and 49% (95% CI, 40% to 
57%) for BRCA2 mutation carriers[12]. These retrospective studies are subject to a 
number of biases [13].  By definition, family based studies require a family history of 
breast cancer and in the case of the BCLC, four affected relatives with breast cancer 
aged <60 years of age or ovarian cancer at any age. By definition therefore, each family 
contained an ‘index’ tested case and additional cases of younger onset breast cancer 
who would likely have been presumed carriers. Many of the analyses in these studies 
were based on assumed mutation status as many at risk relatives were not tested.  Even 
after excluding index cases, most ‘at risk’ relatives were in previous generations.  Risks 
of cancer in birth cohorts prior to 1937 is of  little relevance to  current birth cohorts as 
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it is clear that current risks in both the general population and BRCA1/2   families is 
higher [14-16].  The most important risk to an individual, is their own personal risk 
rather than an averaged assessment based on the effects of BRCA1/BRCA2 or 
MLH1/MSH2 alone. The majority of women being tested currently still have some 
family history of breast cancer. In reality women with a BRCA1 or BRCA2 mutation 
may have risks in a range as large as 20-95%. Many women may be basing decision 
making regarding risk reducing surgery on this information and it is therefore important 
to try to guide them as to where they sit within that range, incorporating both family 
history and other risk factors [17]. 
 
Due to the inherent flaws of retrospective assessments, prospective studies are now 
addressing these risks. These are less biased as they represent current risks for women 
today and can be adjusted for degrees of family history [18,19,20]. However, these 
studies are also affected by shortcomings.  Follow up is still short (only cloned the 
genes within the last 25 years) and as such, any biases in terms of failure of notification 
of cancers or actions that an individual may take to alter a diagnosis could affect 
assessments. About 30% of women undertake risk reducing mastectomy within 2 years 
of presymptomatic testing [17].  Two–three percent of these are identified with occult 
breast cancers [21] which could exaggerate risks. Additionally, if women have their 
first MRI scan soon after gene testing, this could result in a lead time bias by advancing 
the date of diagnosis [22]. Over a long follow up period of 20 years or so this would 
have little effect but most prospective studies still have median follow up of <7 years.  
 
A method of assessing penetrance that has received almost no attention to date is to 
assess penetrance from the results of pre-symptomatic tests in first degree relatives of a 
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mutation carrier who have a 50% initial a priori likelihood of a mutation.  For 
mutations without a phenotype such as cystic fibrosis heterozygotes, the likelihood of a 
mutation would not alter from 50% with age unless the mutation had an effect on life 
expectancy. In moderate to high penetrance conditions such as  BRCA and Lynch 
syndrome,  the proportion of pre-symptomatic positive tests decreases with age 
consistently with penetrance. It is possible to utilise this drop in proportion (using a 
Bayesian calculation) to assess penetrance with age. The reverse of this has been used 
in the past to assess the likelihood of an individual having  a high penetrance disease 
such as Huntington’s disease or neurofibromatosis type 2 without symptoms at older 
age without undertaking genetic testing [23]. To determine the most appropriate risks 
for women attending clinical cancer genetics services we determined the cumulative 
risks of breast and ovarian cancer for 1401 families with pathogenic BRCA1/2 
mutations identified in North West and Central England covering a population of 10 
million and in North West England and East Anglia (population 7 million) for 568 
Lynch syndrome using results of pre-symptomatic testing. 
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Methods 
Index cases and relatives 
Breast and ovarian cancer (BRCA) and Lynch syndrome families have been tested for 
BRCA1/2,  and MLH1 and MSH2 mutations respectively (using a whole gene analysis 
including a test for large deletions) since 1996 in the overlapping regions of Manchester 
and Birmingham in mid-north England and the geographically separate East Anglia 
through the East Anglian Medical Genetics Service. All cancer confirmations and 
genetic testing is undertaken with informed consent. The study was carried out with 
Local Ethical committee approval. Once a BRCA1/2 or MSH2/MLH1 mutation is 
identified, further extensive attempts are made to ensure that all individuals at risk of 
inheriting the family mutation are represented on the pedigree.  All cases of breast or 
abdominal cancers are confirmed by means of hospital/pathology records, from the 
Regional Cancer Registries (data available from 1960) or from death certification. Once 
a family specific pathogenic mutation is identified predictive testing is offered to all 
blood relatives. Where possible all those affected by breast/ovarian/colorectal or other 
relevant cancer are tested to establish the true extent of BRCA1/2 or MSH2/MLH1 
involvement in the family. In many large families it is possible to establish “obligate” 
mutation carriers by testing for the same mutation in different branches of the family, 
thereby establishing that intervening relatives carry the same mutation (these were 
excluded from the analysis). 
 
All BRCA1/2 or MLH1/MSH2 mutation carriers identified were included in this study, 
and their details, those of all tested relatives and first-degree untested female/male 
relatives were entered onto a Filemaker Pro 5 database. The initial individual in which a 
mutation was identified was designated the “index” case, with all other individuals 
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being classified as to their position in the pedigree compared to a proven mutation 
carrier. All men and women who have undergone pre-symptomatic testing as a first 
degree relative (FDR) of a proven mutation carrier were included in the present study. 
Individuals with breast, ovarian, prostate or pancreatic cancer were considered to be 
undergoing ‘diagnostic’ rather than pre-symptomatic testing for BRCA1/2 and were 
excluded. Similarly those diagnosed with a Lynch associated malignancy including 
colorectal, small bowel, endometrial, ovarian, gastric, transitional cell carcinoma of the 
urinary tract, glioma, or prostate cancer were excluded from analysis as pre-
symptomatic tests for MLH1/MSH2. 
 
The proportion testing positive and negative pre-symptomatically in 10-year age 
cohorts: <30 years 30-39 years, 40-49 years, 50-59 years and 60+ years was recorded. 
Obligate carriers who were unaffected but had an affected offspring or those who were 
the parent of a carrier were excluded. Penetrance assessment was undertaken when the 
proportion testing positive dropped below 40% otherwise it was assumed that the 
likelihood was too close to 50% to validate an uplift in penetrance. 
 
Penetrance estimates for related cancer incidence for each gene were derived and also 
by dividing each gene into the previously identified ovarian cancer cluster region 
(OCCR):  exon 11 (nucleotides c.2281to c.4071) for BRCA1 and exon 11 (nucleotides 
c.2830 to c.6401) for BRCA2 (wide definition)[20,24]. For BRCA1 we used the 
nucleotide range identified by the BCLC [20,25,26], which, although not traditionally 
called an OCCR it is the  published region with the highest  proportional risk of ovarian 
cancer. The Manchester scoring system was used to assess the strength of the 
breast/ovarian cancer history [27]. This system was devised to assess the likelihood of a 
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BRCA1/2 mutation and scores breast and ovarian cancers individually in the family, 
giving a higher score the younger the age at diagnosis [27]. Each breast and ovarian 
cancer in a direct lineage is scored with between one point for each gene (breast cancer 
aged 60+) to 6/5 points for BRCA1/2 for a breast cancer under 30-years of age and 8/5 
points for an ovarian cancer aged <60-years. A combined score of 20 reflects a 20% 
likelihood of identifying a BRCA1/2 mutation. 
Penetrance assessment of unaffected FDR relatives undertaking predictive 
genetic testing 
 
The penetrance assessment assumes that there is a 50% likelihood of inheriting the 
family mutation for siblings and offspring (FDRs) of a proven mutation carrier. If it is 
assumed for 100 FDRs that half develop an associated cancer by a certain age then of 
50 assumed carriers, 25 will have developed cancer. The ratio of mutation positive to 
negative will be 25:50 or 1:2 with a 33% chance of testing positive if unaffected at 
that age. For 20% penetrance, the ratio of positive to negative is 0.8:1 while for 33% 
penetrance the ratio is 0.67:1. For 67% penetrance means that 25% women are 
positive or a 1:3 ratio.  
 
Penetrance estimates are not provided for MSH6 and PMS2 as the numbers were too 
small.
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Results 
A total of 2264 unaffected first degree relatives from 1401 index families have 
undertaken pre-symptomatic testing for BRCA1 and BRCA2 gene mutations between  
1996-2017. In BRCA1 families, 364/839 (43.4%) women and 161/307 (52.4%) men 
tested positive, with 383/817 (46.9%) of women and 159/301 (52.8%) of men testing 
positive in BRCA2 families (Table 1). The range (median) of birth years for those 
testing positive was 1914-1998 (1969). 
 
Whilst the proportion of women testing positive for BRCA1 dropped below 40% aged 
40-49 years (p=0.026), this did not occur in BRCA2 until aged 50-59 (p=0.12) and 
was not significantly below 50% until aged 60+ (p=0.01). Assessment of penetrance 
in women based on breast or ovarian cancer diagnosis is presented in table 2. The 
median age for those testing age 60+ was 68 for both genes equating to cancer 
penetrance of 70% for BRCA1 and 56% for BRCA2 by age 68 years. 
 
Amongst men (unaffected by breast, pancreas or prostate cancer) the ratio testing 
positive never dropped significantly below 50% with the older BRCA2 tests actually 
having a ratio above 50%. Nevertheless we are yet to see a BRCA2 related prospective 
cancer in the 46 testing positive aged 60+ years. 
 
Proportions using Manchester score (Manchester cases only) 
 
 
For females, the proportion testing positive for BRCA1 with Manchester score below 
20 and 20+ decreased after age 50 years with non-significantly higher proportion 
testing negative for families with score <20. As for BRCA1, the proportion testing 
positive for BRCA2 with Manchester score of 20+ also decreased after age 50 years 
which was not seen for those from families with scores of <20. Proportional 
differences for BRCA2 were significantly different at age 60+ (p=0.01)(table 3). 
Penetrance estimates in BRCA2 families with a Manchester score of 20+ were 
equivalent to BRCA1 with a penetrance estimate of 71% by age 68.  
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Prospective cancers 
In total, 892 women have had a positive pre-symptomatic test, including 747 FDRs of 
a proven carrier included in the analysis above. Sixty women (6.6%) have been 
diagnosed with breast cancer since pre-symptomatic testing (BRCA1=31; 
BRCA2=29). Nineteen (32%) were diagnosed within 12 months of predictive testing 
(BRCA1=8; BRCA2=11) and nine within 6-months. None were symptomatic at time 
of diagnosis and six were picked up with a prevalence MRI scan with breast cancers 
of 10mm in size or less.  Twenty women had undergone bilateral risk reducing 
mastectomy (BRRM) 0.7-16.2 (median 3.6) years prior to pre-symptomatic testing. A 
further 251 underwent BRRM after testing but 28 as a result of a prospective breast 
cancer diagnosis. Five of the remaining 223 (2.2%) had an occult breast cancer at 
surgery. The rate of breast cancer in the first year post test was 2.8% compared to 
1.5% and 1.8% in years two and three post testing when censored at last follow up, 
mastectomy or breast cancer diagnosis. Seven prospective (BRCA1=4; BRCA2=3) 
ovarian cancers have occurred with two identified as occult at risk reducing surgery 
within one year of genetic testing. Sixty two women had undergone risk reducing 
oophorectomy (0.2-42.7; median 5.76 years) before testing. Seven BRCA1 and 7 
BRCA2 carriers testing positive including an 86 year old BRCA1 carrier (surgery 42.7 
years before) had undergone oophorectomy >5 years before testing. Information on 
those testing negative was not complete with only 24 recorded as having surgery 
before testing and only 3 >5 years before in the >60 year group. After testing a further 
254 have already undertaken risk reducing oophorectomy 143 within 12-months.  
 
OCCR region 
Ratios  for those tested after 50 years when rates of positives have dropped for both 
genes showed some evidence for an OCCR effect on penetrance. For BRCA1 14/62 
(22.6%) tested positive in the OCCR with a median age of 58.18 years and 42/126 
(33.3%) of those from families outside the region at a median age of 57.95 (p=0.17). 
For BRCA2 37/86 (43%) tested positive in the OCCR at a median age of 60.13 
whereas this fell to 39/126 (30.9%) at a median age of 57.5 (p=0.06). 
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Proportion of FDR testing negative 
No adjustment was made for those FDRs that had previously developed breast cancer 
and tested negative. Overall 33/292 (11.4%) of FDRs (index excluded) tested negative 
for the family BRCA1 mutation and 41/342 (12%) for BRCA2. The rates for ovarian 
cancer were 3/151 (2%) and 2/65 (3%) respectively. 
 
Results of classification of Lynch patients by MLH1 and MSH2 gene and age cohort: 
 
In total 646 FDRs in MLH1 (n=299; 154 female) and MSH2 (n=347; 202 female) 
from a total of 568 MMR families have undergone pre-symptomatic testing in 
Manchester and Cambridge. The range of birth years of those testing positive was 
1922-1996 (median 1972). There was evidence to support higher penetrance for 
MLH1 as this was statistically significant for tests age 60 years and over and for all 
tests after age 40 years (table 4). Results for females and males separately are shown 
supplementary table 1. These showed similar penetrance levels of 76% in females and 
67% in males by age 68 years. There were insufficient numbers to break these down 
by gene. There were also insufficient tests in MSH6 (n=83) or PMS2 (n=42) families 
to obtain useful results although testing ratios for MSH6 were 18:9 postive:negative 
and for PMS2 14:10 aged >50years indicating no substantial penetrance. 
 
Discussion 
The present report demonstrates that it is possible to derive penetrance estimates for 
cancer genes on the basis of results of pre-symptomatic tests in FDRs stratified by age. 
We have shown that this confirms high penetrance consistent with estimates from 
recent prospective series [18-20] for BRCA1 and BRCA2 and for MLH1 [28]. The 
results were not as convincing for MSH2 with the ratio only dropping well below 50% 
in the 60+ year group. The results would be considerably strengthened by substantially 
increasing the number of test results in those over 50 years of age.  
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We confirmed evidence for greater overall penetrance for those with BRCA2 mutations 
outside the OCCR but of borderline significance[20]. A large collaborative effort using 
prospective risks from a number of countries,   estimated risks of breast cancer to 80 
years of age  of 72% (95%CI:65-79%) for BRCA1 and 69% (95%CI:61-77%) for 
BRCA2 carriers. BRCA2 mutations outside the OCCR region were associated with a 
significantly greater breast cancer risk compared to those in the broad OCCR 
definition: HR=1.93 (95% CI:1.36-2.74)[20]. BRCA1 mutations located outside the 
region bounded by positions c.2282 to c.4071 were associated with a significantly 
higher breast cancer risk compared to mutations within the region (HR=1.46 
(95%CI:1.11-1.93), p=0.007[20]. This is at odds with our finding of a lower rate of 
positive predictive tests in BRCA1 carriers within the region. This was, however, not 
significant and based on small numbers. Whilst there were large numbers in the 
collaborative study (5046 for both genes at baseline), the median follow up was only 5 
years. We have demonstrated a substantial elevation in cancers in the first year post 
genetic test compared to the following two years. This is likely to be due to a lead time 
effect of baseline MRI along with (to a lesser extent) the identification of occult cancers 
at BRRM. It is not clear if such effects were excluded in the collaborative study [20]. 
Furthermore the end of the follow up period was classified by a variety of means 
including questionnaires with variable intervals, or cancer registry checks and some 
women were lost to follow up. It is likely that there is a margin of error with this short 
follow up time. Nonetheless, we also demonstrated an effect of family history on risks 
in particular in BRCA2. The collaborative study found a 1.91 (95%CI:1.08-3.37) fold 
risk of breast cancer for BRCA2 carriers with a significant family history (two affected 
FDRs) (cumulative risks to age 70: 65% (95%CI: 56-74%) vs 39% (95%CI: 25-56%) 
for those without such history. We were unable to confirm the 1.99 fold relative risk for 
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BRCA1. Interestingly we found no evidence for substantial penetrance in males for 
either BRCA1 or BRCA2. Although substantial increased risks of breast cancer, prostate 
cancer and pancreatic cancer are reported for BRCA2 [29,30] these are less convincing 
for BRCA1 [29,31]. 
 
The results for Lynch syndrome are in keeping with the higher penetrance of MLH1 for 
colorectal cancer in both men and women [28,32]. The higher risks for extra-intestinal 
cancers for MSH2 probably does not equate to similar combined penetrance aged <70 
years [28,33]. Overall penetrance appears similar for men and women. 
 
The results of the present study should not be taken as a replacement for prospective 
studies but, where  a new gene is identified with a reasonably high frequency, less 
biased estimates for penetrance could be derived  in a few years if substantial pre-
symptomatic testing takes place and precedes prospective analysis. Whilst using pre-
symptomatic test ratios in FDRs can only assess combined risks of relevant gene 
associated cancers rather than individual cancers, this is less problematic if there is an 
association with a single cancer type only. For example a gene such as PALB2 (with 
mainly a breast cancer risk although there is a small pancreatic cancer risk) could 
produce unbiased penetrance estimates from pre-symptomatic testing in FDRs before 
prospective studies have matured sufficiently. The method would particularly suit a 
specific cancer predisposition that is rare in the general population. 
 
There are some potential weaknesses of the current study. It has been assumed that the 
ratio of positive to negative mutation results is 50% at birth. There is currently no 
evidence to oppose this assumption. We have also not taken into account the protective 
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effects of risk reducing surgery. The number of patients undergoing risk reducing 
mastectomy  prior to testing  were small and are unlikely to have significantly altered 
the results;  however seven BRCA1 and 7 BRCA2 mutation carriers aged >60 years at 
testing had undergone oophorectomy greater than 5 years prior to  their predictive  test. 
Therefore the contribution of ovarian cancer to penetrance could have been 
underestimated. Unfortunately we do not have complete data on those individuals 
testing negative for their familial  BRCA1/2 mutation to adjust for these cases. It has 
been assumed there is no testing bias in asymptomatic FDRs. It is possible that some 
apparently ‘asymptomatic’ individuals attending for pre-symptomatic testing harbour 
concerns about symptoms that could represent cancer. However, the cancers presenting 
in the first year post testing were all occult detected on surveillance. If there were such 
an effect this would also influence early results for prospective studies. We have also 
not taken into account cancer penetrance in those testing negative for the family 
mutation. The risk of breast cancer in the general population to age 68 years is about 7-
8%, but <1% will have developed ovarian cancer. We have demonstrated both here and 
previously that rates may be higher in FDRs in highly ascertained families [34]. If 
anything, adjustment for this should have increased penetrance at age 68. For Lynch 
syndrome the combined effect of colorectal, endometrial ovarian and other associated 
cancers will have been lower. Table 5 shows adjustment for a 9% population risk of 
BRCA related cancers in women and 4% risk in both sexes of Lynch syndrome cancers 
in those testing negative.  Overall the confidence intervals are still large in the oldest 
category where the final penetrance figures would be obtained, but this could be 
addressed with large-scale collaborative studies. 
 
Conclusion 
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A new approach to assess penetrance using ratios of positive to negative pre-
symptomatic test results in FDRs is presented. This demonstrates high predicted 
penetrance of 70% for BRCA1, 57% for BRCA2 and 95% for MLH1 by age 68 years 
although confidence intervals are large. More robust estimates could be obtained by 
accessing larger number of tests in individuals >70 years of age. 
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Table 1: Number of presymptomatic unaffected FDR females and males undertaking 
predictive genetic testing for BRCA1 and BRCA2 by five age cohort 
Predictive 
test result 
by age  
BRCA1 
positive 
BRCA1 
negative 
%  
 positive 
BRCA1 
BRCA2  
Positive 
BRCA2  
Negative 
% positive  
BRCA2 
FEMALES 
18-30 yrs 96 94 50.53% 73 76 48.99% 
30-39 yrs 134 122 52.34% 134 112 54.47% 
40-49 yrs 80 126 38.83% 101 111 47.64% 
50-59 yrs 35 70 33.33% 48 73 39.67% 
60+ 19 63 23.17% 27 62 30.34% 
total 364 475 364/839
43.4% 
383 434 383/817 
46.88% 
MALES 
18-30 yrs 19 9 67.86% 15 13 53.57% 
30-39 yrs 30 27 52.63% 27 25 51.92% 
40-49 yrs 27 34 44.26% 37 36 50.68% 
50-59 yrs 53 41 56.38% 34 40 45.95% 
60+ 32 35 47.76% 46 28 62.16% 
Total 161 146 161/307  
   52.44% 
159 142 159/301 
52.82% 
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Table 2: Penetrance of BRCA1 and BRCA2 genes assessed among presymptomatic unaffected FDR females undertaking predictive genetic 
testing by gene and age cohort. 
 
Predictive 
test 
result by 
age 
BRCA1 
positive 
BRCA1 
negative 
Positive to 
negative 
ratio 
Penetrance BRCA2  
Positive 
BRCA2  
Negative 
Positive to 
negative 
ratio 
penetrance P value 
18-30 yrs 96 94 1.02 0 73 76 0.96 0 - 
30-39 yrs 134 122 1.10 0 134 112 1.20 0 - 
40-49 yrs 80 126 0.63 0.37 101 111 0.91 0.09* 0.07 
50-59 yrs 35 70 0.5 0.5 48 73 0.66 0.34 0.33 
60+ 19 63 0.30 0.70 27 62 0.43 0.57 0.30 
Total 364 475    383 434    
*Penetrance estimate is provided but as the proportion testing positive was >40% it is unlikely that this 
differs substantially from 0% (see methods) 
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Table 3: proportion of predictive tests positive in unaffected FDR females of five age 
cohort by family Manchester score 20+ and <20 for BRCA1 and BRCA2 genes 
 
BRCA1 
Positive 
<20 
Negative 
<20 
Proportion 
positive  
<20 
% 
Positive 
20+ 
Negative20+ Proportion 
positive 
20+ 
% 
P value 
18-30 
yrs 
25 18 
58% 63 67 48% 
Ns 
30-39 
yrs 
38 18 
68% 77 97 44% 
Ns 
40-49 
yrs 
14 16 
47% 59 103 36% 
Ns 
50-59 
yrs 
4 18 
18% 27 45 38% 
Ns 
60+ 4 13 24% 10 41 20% Ns 
BRCA2 Positive 
<20 
Negative 
<20 
Proportion 
+ve <20 
     % 
Positive 
20+ 
Negative 
20+ 
Proportion 
+ve 20+ 
     % 
P value 
18-30 
yrs 
23 19 
55% 46 54 46% 
Ns 
30-39 
yrs 
39 31 
56% 87 75 54% 
Ns 
40-49 
yrs 
27 15 
64% 72 86 46% 
Ns 
50-59 
yrs 
18 19 
49% 26 50 34% 
0.15 
60+ 12 13 48% 10 35 22% 0.05 
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Table 4: Number of pre-symptomatic unaffected FDR females and males undertaking  
predictive genetic testing for MLH1 and MSH2 genes by age cohort 
For positive pre-symptomatic tests >40 years of age MLH1 significantly less likely to 
be positive p=0.05 
Predictive 
test result by 
age  
Number 
positive 
MLH1 
Number 
negative 
MLH1  
Proportion 
positive 
MLH1 
% 
Ratio Penetrance 
estimate 
18-30 yrs 36 43 45.56% 0.84  
30-39 yrs 42 41 50.60% 1.02  
40-49 yrs 24 52 32.89% 0.46 0.54 
50-59 yrs 14 26 37.5% 0.54 0.46 
60+ 1 19 5% 
0.052 
0.95  
P=0.034* 
Total 117 181 117/298   
 Number 
positive 
MSH2 
Number 
negative 
MSH2  
Proportion 
positive 
MSH2 
% Ratio 
 
18-30 yrs 46 41 52.87% 1.12  
30-39 yrs 44 47 48.35% 0.94  
40-49 yrs 28 39 41.79% 0.72  
50-59 yrs 22 19 53.66% 1.16  
60+ 17 44 27.87% 0.39 0.61 
Total 157 190 157/190   
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Table 5: Adjusted penetrance estimates to 68 years of age for BRCA1, BRCA2, MLH1 
and MSH2 genes taking into account cancer incidence in negative testing group 
 
 
 
 
 
 
. 
Predictive 
test result by 
age  
Number 
positive 
MLH1 
Number 
negative 
MLH1  
Ratio Penetrance 
estimate 
95% CI 
BRCA1 19 69 0.27 0.73 0.61 – 0.82 
BRCA2 27 68 0.40 0.60 0.49 – 0.71 
BRCA2 MSS 
20+ 
         10
  
38 0.26 0.74 0.58 – 0.85 
MLH1 1 20           0.05 0.95 0.76 - 0.99 
MSH2 17 46 0.39 0.61 0.49 – 0.76 
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